Invest in intelligence that delivers

Ocrevus Use Still Growing in Europe But Challenges on Horizon, Spherix Reports

From: Multiple Sclerosis News Today

By: Marta Figueiredo

Multiple Sclerosis News Today

Prescriptions of Roche’s Ocrevus (ocrelizumab) among multiple sclerosis (MS) patients initiating or switching a disease-modifying…

 

Sign up for alerts, market insights and exclusive content in your inbox.

Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:

HEMATOLOGY

Throughout 2024, we will be publishing over
10 groundbreaking studies covering a wide range of indications within classical hematology.